-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of tipranavir in treatment of patients with multidrug-resistant HIV
Review
(1334) Views (396) Full article downloads
Authors: Joshua D Courter, Colleen J Teevan, Michael H Li, et al
Published Date September 2010
Volume 2010:6 Pages 431 - 441
DOI: http://dx.doi.org/10.2147/TCRM.S4207
Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,31University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USA
Abstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.
Keywords: tipranavir, HIV, multidrug resistance
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Editorial
Nonpathogenic bacterial flora and immunoglobulin A in the oral cavity inhibit colonization of methicillin-resistant Staphylococcus aureus in very low birth weight infants
A review of studies concerning treatment adherence of patients with anxiety disorders
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Evaluation of factors influencing stable microbubble test results in preterm neonates at 30–33 gestational weeks
Major risk factors for the appearance of white-matter lesions on MRI in hypertensive patients with controlled blood pressure
Erythrocyte sedimentation rate as a marker for coronary heart disease
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




